Modeling Alzheimer's Disease Neuroinflammation for Drug Discovery
Human Neural Organoid Modeling of Alzheimer's Disease Neuroinflammation for Drug Discovery
['FUNDING_SBIR_1'] · STEM PHARM, INC. · NIH-10758939
This study is looking at how inflammation in the brain affects Alzheimer's Disease by creating tiny brain-like structures to see how immune cells react to the harmful proteins and dying brain cells, with the hope of finding new treatments that could help people with Alzheimer's.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STEM PHARM, INC. (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10758939 on ClinicalTrials.gov |
What this research studies
This research investigates how neuroinflammation contributes to Alzheimer's Disease (AD) by creating human neural organoids that mimic the disease's environment. Using advanced hydrogel technology, the study incorporates microglia, the brain's immune cells, into these organoids to observe their responses to amyloid-beta plaques and dying neurons. This approach aims to better understand the inflammatory processes involved in AD and to facilitate drug discovery by providing a more accurate model of the disease. Patients may benefit from insights gained that could lead to new treatments targeting neuroinflammation in AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's Disease, particularly those with genetic predispositions linked to neuroinflammation.
Not a fit: Patients who do not have any genetic risk factors for Alzheimer's Disease or who are not experiencing neuroinflammatory symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that specifically target neuroinflammation in Alzheimer's Disease.
How similar studies have performed: Other research has shown success in using organoid models to study neurodegenerative diseases, indicating that this approach has potential for meaningful advancements.
Where this research is happening
MADISON, UNITED STATES
- STEM PHARM, INC. — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEBAKKEN, CONNIE S — STEM PHARM, INC.
- Study coordinator: LEBAKKEN, CONNIE S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.